Showing results (91-100 of 137) with videos related to
Sort By:
Pageof 14
Acta Oncologica (Stockholm, Sweden)|August 9, 2020
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumabAlex Friedlaender, Giulio Metro, Diego Signorelli, et al.Cancers|January 25, 2025
The Rare Entity of Basaloid Thymic Carcinoma: A Multicentric Retrospective Analysis from the Italian Collaborative Group for ThYmic MalignanciEs (TYME)Chiara Catania, Sara Manglaviti, Paolo Zucali, et al.Frontiers in Immunology|October 7, 2022
Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLCDiego Signorelli, Patrizia Ghidotti, Claudia Proto, et al.Journal of Thoracic Disease|February 8, 2020
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohortGiulio Metro, Alfredo Addeo, Diego Signorelli, et al.European Journal of Cancer (Oxford, England : 1990)|April 6, 2021
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access programArsela Prelaj, Achille Bottiglieri, Claudia Proto, et al.Tumori|February 19, 2024
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% FundLuigi Cerbone, Sara Delfanti, Stefania Crivellari, et al.Lung Cancer (Amsterdam, Netherlands)|January 9, 2021
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkersRiccardo Lobefaro, Giuseppe Viscardi, Raimondo Di Liello, et al.Lung Cancer (Amsterdam, Netherlands)|November 15, 2022
Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP)Antonio Passaro, Giuseppe Lo Russo, Francesco Passiglia, et al.Clinical Lung Cancer|November 9, 2020
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab MonotherapyGiannis Mountzios, Alessandro de Toma, Panagiota Economopoulou, et al.Clinical Lung Cancer|April 16, 2020
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External ValidationArsela Prelaj, Giuseppe Lo Russo, Claudia Proto, et al.Pageof 14